Cystatin C as a potential biomarker for dosing of renally excreted drugs

25Citations
Citations of this article
42Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The objective of the present study was to review the available pharmacokinetic evidence for the utility of cystatin C (CysC) as a marker of renal function to predict the dose of renally excreted drugs.The bibliographic search used PubMed and EMBASE databases, from its inception through to January 2014, with the following keywords 'pharmacokinetics' and 'cystatin C'.Sixteen pharmacokinetic publications were identified and seven drugs primarily excreted by the kidney were studied. Among them, only one study was performed in children, the others were performed in adults and/or elderly subjects, either healthy volunteers or patients with variable clinical conditions, such as cystic fibrosis and cancer. Most of studies (n = 13/16) demonstrated that CysC was better correlated with clearance/trough concentration of evaluated drugs compared with creatinine.Our review supports that CysC is a good marker of renal function to predict dose of renally excreted drugs. Efforts should be made to evaluate the impact of CysC in special populations in order to define its clinical value in dosing optimization.

Cite

CITATION STYLE

APA

Brou, N. A., Jacqz-Aigrain, E., & Zhao, W. (2015). Cystatin C as a potential biomarker for dosing of renally excreted drugs. British Journal of Clinical Pharmacology, 80(1), 20–27. https://doi.org/10.1111/bcp.12602

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free